What are the mechanisms of lipotoxicity in NASH ?
Prof Cusi, USA presents his views on this important topic for all those interested in the diagnosis and management of NASH.
Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH
Learn more about the burden of the disease, Prof Sven Francque, Belgium
What are the current definitions ? Prof Abdelmalek, USA
An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA

    5th edition of the Paris Nash Meeting

    The 5th edition of the Paris Nash Meeting is being held at the Institut Pasteur in Paris. Many of the Pannash experts are attending the conference. This is an opportunity to remember the importance of screening for Liver disease. In France, according to the cohort Constance, the prevalence of Liver disease is 18.2% of the adult French population which is 7.83 million people and 2.6% of the population with advanced disease is more than 200,000 people with a high risk of developing cirrhosis and / or liver cancer.


    Can you make the difference between NAFLD and NASH ?

    An understanding of the pathogenesis and natural course of NAFL and NASH is essential to develop new treatments and design clinical trials. These conditions are not static, but dynamic, and may progress or regress at variable rates in different individuals or even in the same individual at different times.


    Is NASH only about the liver ?

    Prof Jean-François Dufour, Switzerland sheds lights on this important question.


    The PanNASH initiative experts

    The PanNASH initiative is led by an international, multidisciplinary expert committee

    • Medical experts in areas related to NASH such as hepatology, diabetes, and cardiology
    • Scientific experts focused on promoting a better understanding of the pathophysiological mechanisms involved in NASH


    The globalization of NAFLD

    It is estimated that 25% of the global adult population is potentially affected by non-alcoholic fatty liver disease (NAFLD), with the highest prevalence in the Middle East and South America and the lowest in Africa.


    Focus : NASH is associated with some degree of hepatic fibrosis.

    Liver biopsy studies suggest that fibrosis progresses at a rate of approximately one stage per decade, suggesting that stage 2 fibrosis will progress to cirrhosis within 20 years.


    Video : insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA

    NAFLD and NASH are substantial public health and economic burden.


    Focus : Type 2 diabetes mellitus

    Type 2 diabetes mellitus (T2DM) is present in about 23% of NAFLD patients and about 44% of NASH patients.(7) Moreover, NAFLD oftentimes precedes T2DM.

Contact Information

Yann Colardelle / Med Ed GS
27 rue Raffet, 75016 Paris, France